Plasminogen activator inhibitor-1 gene polymorphism as a risk factor for vascular complications in type 2 diabetes mellitus
Tóm tắt
Từ khóa
Tài liệu tham khảo
Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2-diabetes: principles of pathogenesis and therapy. Lancet 9467:1333–1346. https://doi.org/10.1016/S0140-6736(05)61032-X
Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res ClinPract 103:137–149. https://doi.org/10.1016/j.diabres.2013.11.002
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R et al (2017) Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 135:e146–e603. https://doi.org/10.1161/CIR.0000000000000485
Low Wang CC, Hess CN, Goldfine AB (2016) Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus – mechanisms, management, and clinical considerations. Circulation 133:24. https://doi.org/10.1161/CIRCULATIONAHA.116.022194
Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G (2000) Tissue plasminogen activator, plasminogen activator inhibitor-1, andtissue plasminogen activator/plasminogen activator inhibitor-1 complexas risk factors for the development of a first stroke. Stroke 31:26–32
Rabieian R, Boshtam M, Zareei M, Kouhpayeh S, Masoudifar A, Mirzaei H (2018) Plasminogen Activator Inhibitor Type-1 as a Regulator of Fibrosis. J Cell Biochem 119:17–27
Crandall DL, Quinent EM, Morgan GA, Busler DE, Mchendry-Rinde B, Kral AG (1999) Synthesis and Secretion of Plasminogen Activator Inhibitor-1 by Human Preadipocytes. J Clin Endocrinol Metab 84(9):3222–3227
Chevilley A, Lesept F, Lenoir S, Ali C, Parcq J, Vivien D (2015) Impacts of tissue-type plasminogen activator (tPA) on neuronal survival. Front Cell Neurosci. 9:415
Eriksson P, Kallin B, van’t Hooft FM, Båvenholm P, Hamsten A (1995) Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 92:1851–1855
Nauck M, Wieland H, Marz M (1999) Rapid Homogeneous Genotyping of the 4G/5GPolymorphism in the Promoter Region of the PAI1Gene by Fluorescence Resonance Energy Transfer and Probe Melting Curves. Clinical Chemistry 45(8):1141–1147
Nordt TK, Lohrmann J, Bode C (2001) Regulation of PAI-1expression by genetic polymorphism. Impact on atherogenesis. Thromb Res 103(Suppl 1):S1–S5
Serrano Rios M (2007) The 4G/4G PAI-1 genotype is associated with elevated plasma PAI-1 levels regardless of variables of the metabolic syndrome and smoking status. A population-based study in Spanish population. Diab Obes Metab 9:134–136
Boeckoldt SM, Bijsterveld NR, Moon AH, Levi M, Buller HR, Peters RJ (2001) Genetic variation in coagulation and fibrinolyticprotein and their relation with acute myocardial infarction: asystematic review. Circulation 104:3064–3068
Kholer HP, Grant PJ (2000) Plasminogen-activator inhibitor type1 and coronary artery disease. N Engl J Med. 342:1792–1801
Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT Jr, Reiner AP (2002) The association of PAI-1 promoter 4G/5Ginsertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk 9:131–137
Vaughan DE, Rai R, Khan SS, Eren M, Ghosh AK (2017) Plasminogen Activator Inhibitor-1 Is a Marker and a Mediator of Senescence. Arterioscler Thromb Vasc Biol 37:1446–1452
Duggan E, O’Dwyer MJ, Caraher E, Diviney D, McGovern E, Kelleher D, McManus R and Ryan T (2007) Coagulopathy After Cardiac Surgery May Be Influenced by a Functional Plasminogen Activator Inhibitor Polymorphism. AnesthAnalg 104(6):1343–1347
Paneni F, Beckman JA, Creager MA, Cosentio F (2013) Diabetes and Vascular Disease Pathophysiology, Clinical Consequences, and Medical Therapy: Part I. Eur Hear J 30(31):2436–2443
Zhao L, Huang P (2013) Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with type 2 diabetes risk. Int J ClinExp Med. 6(8):632–640
Liang XN, Xie L, Cheng JW, Tan Z, Yao J, Liu Q et al (2013) Association between PAI-1 4G/5GPolymorphisms and osteonecrosis of femoral head: a meta-analysis. Thromb Res. 132(2):158–163
Cesari M, Pahor M, Incalzi RA (2010) Plasminogen activator inhibitor-1 (PAI-1): A key factor linking fibrinolysis and age-related subclinical and clinical conditions. CardiovascTher. 28(5):e72–e79
Xie X, Shi X, Xun X, Rao L (2017) Endothelial nitric oxide synthase gene single nucleotide polymorphisms and the risk of hypertension: a meta-analysis involving 63,258 subjects. Clin Exp Hypertens 39(2):175–182
Nilsson JB, Boman K, Jansson JH, Nilsson T, Näslund U (2008) The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase. J Thromb Thrombolysis 26:188–195
Wijesuriya MA, De-Arbew WK, Weerathunga A et al (2012) Association of chronic complications of type 2 diabetes with the biochemical and physical estimations in subjects attending single visit screening for complications. J Diabetol:1–3
Elnaggar AA, Fawzy MM, Nabawy EL, Kamal MM, Ibrahim NM (2017) The Association of Plasminogen Activator Inhibitor (PAI-1) Level and 4G/5G Gene Polymorphism with Diabetic Nephropathy in Type 2 Diabetes Mellitus. J Am Sci 13(11)
Rahimi M, HasanVand A, Rahimi Z et al (2010) Synergestic effects of MTHFR C677Tpolymorphisms on the increased risk of microand macro-albuminuria and progression ofdiabetic nephropathy among Iranians with type IIdiabetes mellitus. Clin Biochem 43:1333–1339
Mtiraoui N, Ezzidi I, Chaib M et al (2017) MTHFR C677T and A1298C gene polymorphism and hyperhomocysteinemia as a risk factor for diabetic nephropathy in diabetic patients. Diabet Res Clin Pract. 75:99–106
Eroglu Z, Erdogan M, Tetik A, Xilmaz C (2007) The relationship of MTHFR C677T gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabet Metab Res Rev 23:621–624
Madan R, Gupta B, Saluja S et al (2010) Coagulation Profile in Diabetes and itsAssociation with Diabetic MicrovascularComplications. JAPI 58:481–484
Salas II, Miranda AL, Sainz IM, Maldonado RE, Sánchez GB (2009) Association of the Plasminogen Activator Inhibitor-1 Gene 4G/5G Polymorphism with ST Elevation Acute Myocardial Infarction in Young Patients. Rev Esp Cardiol 62 (4):365–372
Abdel Rasol HA, Attia FM, Ismail S, Abdel Azeem AA, Nowier SR, Aziz MA, Osman ZM (2012) Association between 4G/4G plasminogen activator inhibitor-1 polymorphism, PAI-1 activity, and diabetic retinopathy. Egypt J Haematol [serial online] [cited 2019 Apr 21] 37:81–87
Xu K, Xiaoyun L, Yang F, Cui D, Yun S, Chong S, Tang W, Yang T (2013) PAI-1 -675 4G/5G Polymorphism in association with diabetes and diabetic complications susceptibility: a meta-analysis study. PLoS One 8(11):e79150. https://doi.org/10.1371/journal.pone.0079150
Franco RF, Reitsma PH (2011) Gene polymorphisms of the haemostatic system and the risk of arterial thrombotic disease. Br J Haematol 115:491–506